NCT02027116

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection

Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: GeneOne Life Science, Inc. · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety, tolerability and immunogenicity of VGX-6150 as second-line therapy in chronic hepatitis C patients

Conditions

• Hepatitis C, Chronic

Interventions

Type	Name	Description
BIOLOGICAL	VGX-6150	Plasmid DNA delivered via IM injection with electroporation

Timeline

• Start date: 2014-01-01
• Primary completion: 2015-07-01
• Completion: 2017-07-01
• First posted: 2014-01-03
• Last updated: 2017-08-07

Locations

2 sites across 1 country: South Korea